Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Vol. 17, 04 December 2023
* Author to whom correspondence should be addressed.
This research mainly introduces the symptoms and harms of Parkinson's disease, as well as the mainstream treatment methods in the past five years and potential treatments for Parkinson's disease (PD) in the future. First of all, it talks about a biological treatment of PD. Levodopa and dopamine, which is currently the main drug used to relieve PD motor symptoms. It helps patients reduce motor symptoms as much as possible by supplementing the lack of dopamine in the brain. Secondly, it talks about MAO-B inhibitors, like medicine rasagiline and selegiline. These drugs increase dopamine availability by inhibiting dopamine metabolism, thereby reducing the symptoms of PD while reducing potential drug side effects. In addition, this research introduces two potential treatments for PD that are under development: nanomedicine and deep brain stimulation (DBS). The application of nanomedicine in PD treatment such as how it can improve the lives of PD patients through innovative methods in drug delivery, early diagnosis and nerve repair and some potential problems of nanomedicine during PD treatment, and how deep brain stimulation, a surgical treatment, can significantly reduce the symptoms of PD by implanting electrodes and stimulating specific brain areas, thereby improving patients' quality of life.
Parkinson's Disease, Drug Treatment, Application
1. Rao S S, Hofmann L A, Shakil A. 2006 American family physician 74(12) 2046-2054
2. Jankovic J, Tan E K. 2020 Journal of Neurology, Neurosurgery & Psychiatry 91(8) 795-808
3. Lasoń W, Jantas D, Leśkiewicz M, et al. 2023 Cells 12(4) 660
4. Kwon D K, Kwatra M, Wang J, et al. 2022 Cells 11(23) 3736
5. Radhakrishnan D M, Goyal V. 2018 Neurology India 66(7) 26
6. Jost W H. 2022 Journal of Neural Transmission 129(5-6) 723-736
7. Jagaran K, Singh M. 2021 International Journal of Molecular Sciences 22(16) 9082
8. Iarkov A, Barreto G E, Grizzell J A, et al. 2020 Frontiers in Aging Neuroscience 12 4
9. Yu Y, Wang X, Wang Q, et al. 2020 Applied mathematics and mechanics 41(12) 1747-1768
10. Little S, Brown P. 2020 Movement Disorders 35(4) 555-561
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).